Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01256151 · ClinicalTrials.gov registry record · Phase 1
Pharmacokinetics Of Alprazolam Sublingual Tablet Versus Conventional Tablet
A Phase 1 study, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris.
- Completed
- Registry status
- Phase 1
- Development phase
- 28
- Enrollment target
NCT01256151: Completed Phase 1 study, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris.
NCT01256151 is a Phase 1 study that has completed, run by Pfizer's Upjohn has merged with Mylan to form Viatris. The registered enrollment target is 28 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (53% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01256151, a Phase 1 study, has completed, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 28 participants
- Enrollment target
Study Summary
To assess if the sublingual tablet will have similar pharmacokinetics as the conventional tablet of alprazolam.
Interventions
- DRUG Alprazolam tablet
- DRUG Alprazolam sublingual
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2011-01 |
| Est. Completion | 2011-05 |
| Phase | Phase 1 |
What the finished NCT01256151 record still lists
NCT01256151 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 28 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (53% lower).
The record links to 0 conditions, and to 2 interventions - of which Alprazolam tablet is the first listed.
NCT01256151 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01256151 about?
NCT01256151 is a clinical study titled "Pharmacokinetics Of Alprazolam Sublingual Tablet Versus Conventional Tablet". To assess if the sublingual tablet will have similar pharmacokinetics as the conventional tablet of alprazolam.
What is the current status of trial NCT01256151?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 28 participants. The study started on 2011-01. Estimated completion is 2011-05.
What interventions are being tested in trial NCT01256151?
The interventions under investigation include: Alprazolam tablet (DRUG), Alprazolam sublingual (DRUG).
Who is sponsoring clinical trial NCT01256151?
This trial is sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris, which has 158 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01256151's enrollment target sits among peer trials
28 1447th of 2000 higher than 538 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03471117 · 28 participants · Phase 4
Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients
- NCT03523975 · 28 participants · Phase 1
Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma
- NCT03608631 · 28 participants · Phase 1
iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation
- NCT03810651 · 28 participants · Early Phase 1
Pencil Beam Scanning in Patients With Renal Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia